Therapeutic evaluation of monoclonal antibody-maytansinoid conjugate as a model of RON-targeted drug delivery for pancreatic cancer treatment.

about

Aptamer-Drug Conjugates of Active Metabolites of Nucleoside Analogs and Cytotoxic Agents Inhibit Pancreatic Tumor Cell Growth Emerging cancer-specific therapeutic aptamers.A missing link between RON expression and oncological outcomes in resected left-sided pancreatic cancer.

P2860

Q36316911-7389E59C-B9F7-4F39-A8E9-F3ADEE55CA4B Q39425770-FE8136ED-3FD8-4C31-AD39-C3C42BB2A5D0 Q41701927-53E6F440-354A-4E48-A4B7-471E3082A74A

P2860

Therapeutic evaluation of monoclonal antibody-maytansinoid conjugate as a model of RON-targeted drug delivery for pancreatic cancer treatment.

Item

http://www.wikidata.org/entity/Q36958365

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Therapeutic evaluation of mono ...... r pancreatic cancer treatment.

@en

type

Item

label

Therapeutic evaluation of mono ...... r pancreatic cancer treatment.

@en

prefLabel

Therapeutic evaluation of mono ...... r pancreatic cancer treatment.

@en

P1476

Therapeutic evaluation of mono ...... r pancreatic cancer treatment.

@en

P2093

Hang-Ping Yao

http://www.w3.org/2001/XMLSchema#string

Jian-Wei Zhou

http://www.w3.org/2001/XMLSchema#string

Liang Feng

http://www.w3.org/2001/XMLSchema#string

Ming-Hai Wang

http://www.w3.org/2001/XMLSchema#string

Rui-Wen Zhang

http://www.w3.org/2001/XMLSchema#string

P2860

Discovery of N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide (BMS-777607), a selective and orally efficacious inhibitor of the Met kinase superfamily

Cyclin D as a therapeutic target in cancer

Antibody therapy of cancer

A novel putative receptor protein tyrosine kinase of the met family

Ron knockdown and Ron monoclonal antibody IMC-RON8 sensitize pancreatic cancer to histone deacetylase inhibitors (HDACi)

Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies

Drug combination studies and their synergy quantification using the Chou-Talalay method

Maytansine and cellular metabolites of antibody-maytansinoid conjugates strongly suppress microtubule dynamics by binding to microtubules

Therapeutic implications of a human neutralizing antibody to the macrophage-stimulating protein receptor tyrosine kinase (RON), a c-MET family member.

KRAS, Hedgehog, Wnt and the twisted developmental biology of pancreatic ductal adenocarcinoma.

P304

937-956

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27293990

http://www.w3.org/2001/XMLSchema#string

P921

drug delivery

P932

4889711

http://www.w3.org/2001/XMLSchema#string

Therapeutic evaluation of monoclonal antibody-maytansinoid conjugate as a model of RON-targeted drug delivery for pancreatic cancer treatment.

about

P2860

P2860

Therapeutic evaluation of monoclonal antibody-maytansinoid conjugate as a model of RON-targeted drug delivery for pancreatic cancer treatment.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P433

P478

P577

P698

P921

P932

P1433

P1476

P2093

P2860

P304

P31

P433

P478

P577

P698

P921

P932